Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin Hydrate in Japan

 Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin Hydrate in Japan

Chugai and Sanofi to Terminate their Licensing Agreement for Tofogliflozin Hydrate in Japan

Shots:

  • Chugai and Sanofi terminate their 2012 licensing agreement, allowing Sanofi to transfer marketing rights of Apleway to Kowa as of Apr 01, 2020 with the anticipated transfer of marketing authorization in Jun’2020
  • In 2012, Chugai granted Kowa & Sanofi commercial rights of tofogliflozin 20mg under the brand name Deberza & Apleway respectively, following the regulatory approvals in 2014
  • Tofogliflozin hydrate is an SGLT2 selective inhibitor act by lowering blood glucose thus inhibiting glucose reabsorption in the renal tubule and inducing excretion of excess blood glucose into the urine

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Chugai

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post